Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Aug
17
Today In Oncology
What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy
Can Newborn Genetic Testing Identify Cancer Predisposition Genes
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
QOL Impact of Postmastectomy Chest Wall Radiotherapy 5-Year Follow-up
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo